Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson's disease GBA-N370S dopamine neurons

翻译后蛋白质组学平台揭示帕金森病GBA-N370S多巴胺神经元神经突生长受损

阅读:4
作者:Helle Bogetofte ,Brent J Ryan ,Pia Jensen ,Sissel I Schmidt ,Dana L E Vergoossen ,Mike B Barnkob ,Lisa N Kiani ,Uroosa Chughtai ,Rachel Heon-Roberts ,Maria Claudia Caiazza ,William McGuinness ,Ricardo Márquez-Gómez ,Jane Vowles ,Fiona S Bunn ,Janine Brandes ,Peter Kilfeather ,Jack P Connor ,Hugo J R Fernandes ,Tara M Caffrey ,Morten Meyer ,Sally A Cowley ,Martin R Larsen ,Richard Wade-Martins

Abstract

Variants at the GBA locus, encoding glucocerebrosidase, are the strongest common genetic risk factor for Parkinson's disease (PD). To understand GBA-related disease mechanisms, we use a multi-part-enrichment proteomics and post-translational modification (PTM) workflow, identifying large numbers of dysregulated proteins and PTMs in heterozygous GBA-N370S PD patient induced pluripotent stem cell (iPSC) dopamine neurons. Alterations in glycosylation status show disturbances in the autophagy-lysosomal pathway, which concur with upstream perturbations in mammalian target of rapamycin (mTOR) activation in GBA-PD neurons. Several native and modified proteins encoded by PD-associated genes are dysregulated in GBA-PD neurons. Integrated pathway analysis reveals impaired neuritogenesis in GBA-PD neurons and identify tau as a key pathway mediator. Functional assays confirm neurite outgrowth deficits and identify impaired mitochondrial movement in GBA-PD neurons. Furthermore, pharmacological rescue of glucocerebrosidase activity in GBA-PD neurons improves the neurite outgrowth deficit. Overall, this study demonstrates the potential of PTMomics to elucidate neurodegeneration-associated pathways and potential drug targets in complex disease models.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。